Eisai Reports Impressive Leqembi Sales of 29.3 Billion Yen in Q2 2026

Eisai's Leqembi® Achieves Significant Sales Growth

In an impressive display of market performance, Eisai Co., Ltd. has reported that Leqembi® (lecanemab), developed in collaboration with BioArctic AB, posted total sales of 29.3 billion yen in the second quarter of 2026. This announcement coincided with Biogen’s quarterly report, marking a positive financial milestone for the partnership.

Royalty Revenue Growth

The sales figure translates to a royalty payment of approximately SEK 179 million to BioArctic, reflecting a roughly 10 percent increase compared to the same quarter in 2025. Notably, the previous year’s results incorporated a one-time stockpiling effect in the Chinese market, amounting to about JPY 5.3 billion. If this effect is excluded, the royalty revenues for Q2 2026 exhibit a noteworthy 43 percent growth in relation to the prior year. This surge signifies not only the strong demand for Leqembi but also the effectiveness of BioArctic and Eisai's strategies in marketing the treatment globally.

Upcoming Financial Reports

BioArctic is set to release its full financial report for Q2 2026 on August 26, 2026, offering further insights into its overall performance and strategies moving forward. Such transparency is crucial for investors and stakeholders, especially given the burgeoning interest in neurodegenerative treatments in recent years.

About Leqembi®

Leqembi® is recognized as a groundbreaking treatment in the fight against Alzheimer's disease. Developed through an extensive research collaboration between BioArctic and Eisai, this innovative drug is a humanized monoclonal antibody targeting aggregated forms of amyloid-beta (Aβ), which are implicated in the progression of Alzheimer's. Currently, Leqembi is approved in 53 countries and is undergoing regulatory reviews in six additional markets, reflecting its global reach and recognition.

In the United States, Leqembi is particularly notable for its approval for subcutaneous dosing with an autoinjector, making administration more accessible for patients with early Alzheimer's disease. Moreover, ongoing clinical trials, such as the Phase 3 study AHEAD 3-45 involving preclinical Alzheimer's patients, emphasize the commitment of Eisai and BioArctic towards advancing neurodegenerative research.

Strategic Alliance and Future Prospects

Since 2005, BioArctic has partnered with Eisai to innovate and commercialize treatments specifically targeting Alzheimer's disease. Important agreements, such as the Development and Commercialization accord signed in 2007, have been pivotal in guiding the development of Leqembi and associated therapies. BioArctic holds the rights to commercialize Leqembi in the Nordic region and is poised to leverage its partnership with Eisai for broader market access.

In summary, the latest sales figures for Leqembi® underscore the growing demand for Alzheimer’s therapies while demonstrating the effective collaboration between Eisai and BioArctic. With ongoing studies and expanding global reach, Leqembi appears firmly positioned for continued success in the rapidly evolving pharmaceutical landscape.

Conclusion

The recent financial results from Eisai regarding Leqembi represent not only a success for the company but also a hopeful advancement in Alzheimer's treatment options globally. As ongoing clinical trials unfold and more regions approve the drug, the future seems promising for both those affected by Alzheimer's and the companies devoted to finding solutions.